Headache News and Research RSS Feed - Headache News and Research

In medicine a headache or cephalalgia is a symptom of a number of different conditions of the head. Some of the causes are benign while others are medical emergencies.
Further Reading
FDA approves GlaxoSmithKline’s Arnuity Ellipta for treatment of asthma

FDA approves GlaxoSmithKline’s Arnuity Ellipta for treatment of asthma

GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older. Arnuity is not indicated for relief of acute bronchospasm. [More]
Rheumatologic diseases can initially present as neurological disorders, delay diagnosis for many months

Rheumatologic diseases can initially present as neurological disorders, delay diagnosis for many months

Lupus and other rheumatologic diseases can initially present as neurological disorders such as headaches and seizures, and thus delay diagnosis for many months, according to Loyola University Medical Center neurologists. [More]
Doctors test device designed to 'turn off' cluster headaches

Doctors test device designed to 'turn off' cluster headaches

For those suffering excruciating pain from cluster headaches, relief may soon be available from an investigational device being studied in a national multicenter clinical trial. Recently, doctors at The Ohio State University Wexner Medical Center performed the first surgery in the United States to insert a neurostimulator to provide relief from cluster headaches, which are more painful than migraines. [More]
Treatments that involve neck manipulation may be linked with strokes

Treatments that involve neck manipulation may be linked with strokes

Treatments that involve neck manipulation may be associated with strokes, although this association is not proven, according to an American Heart Association Scientific Statement written by lead author Dr. Jose Biller of Loyola University Medical Center and other stroke experts. [More]
First Edition: August 12, 2014

First Edition: August 12, 2014

Today's headlines include stories about how the federal government's experience with healthcare.gov has led to the creation of the U.S. Digital Service. [More]
Plan International outlines strategies to combat Ebola outbreak

Plan International outlines strategies to combat Ebola outbreak

The current Ebola outbreak, the most severe and complex in history, is now making its impact felt worldwide. [More]
Herpes zoster vaccine effective in protecting older adults against shingles, even after chemotherapy

Herpes zoster vaccine effective in protecting older adults against shingles, even after chemotherapy

The herpes zoster vaccine continues to be effective in protecting older adults against shingles, even after they undergo chemotherapy, according to a Kaiser Permanente study published today in the journal Clinical Infectious Diseases. [More]
Study confirms benefit of surgical treatment for migraines

Study confirms benefit of surgical treatment for migraines

Dr. Oren Tessler, Assistant Professor of Clinical Surgery at LSU Health Sciences Center New Orleans School of Medicine, is part of a team of plastic and reconstructive surgeons who report a high success rate using a method to screen and select patients for a specific surgical migraine treatment technique. [More]
Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

Today Biogen Idec announced that the European Commission (EC) has granted marketing authorization for PLEGRIDY (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). [More]
Paracetamol fails to beat placebo at relieving back pain

Paracetamol fails to beat placebo at relieving back pain

Paracetamol is no more effective than placebo at relieving acute lower back pain, according to new clinical trial results. [More]

Narrow networks backlash being felt across the insurance marketplace and campaign trail

News outlets report that consumer frustration with health law plans' limited choice of doctors and hospitals is emerging in a number of areas. [More]
Immunosignaturing holds promise for accurate diagnosis of Valley Fever

Immunosignaturing holds promise for accurate diagnosis of Valley Fever

On July 5, 2011, a massive wall of dust, ("haboob," in Arabic), blanketed Phoenix, Arizona, creating an awesome spectacle, (or stubborn nuisance, depending on your perspective). Dust storms are a common occurrence in the arid desert environments of the American Southwest. [More]
Combination superior to monotherapy for COPD

Combination superior to monotherapy for COPD

Combination treatment with umeclidinium plus vilanterol improves lung function in patients with chronic obstructive pulmonary disease to a greater extent than with VI or tiotropium monotherapy, results show. [More]
First Edition: July 22, 2014

First Edition: July 22, 2014

Reporting for Kaiser Health News, Susan Jaffe writes: "Medicare officials have allowed patients at dozens of hospitals participating in pilot projects across the country to be exempted from the controversial requirement that limits nursing home coverage to seniors admitted to a hospital for at least three days. [More]
Chikungunya virus transmission occurs in Florida for the first time

Chikungunya virus transmission occurs in Florida for the first time

The chikungunya virus, which is transmitted to people by mosquitoes (Aedes aegypti and Aedes albopictus), was found for the first time in the Americas on islands in the Caribbean in December 2013. Yesterday, the first case of chikungunya in the continental United States was reported in a man from Florida who had not recently travelled outside the United States. [More]
FDA approves Ruconest for treatment of acute attacks in adolescent patients with HAE

FDA approves Ruconest for treatment of acute attacks in adolescent patients with HAE

The U.S. Food and Drug Administration yesterday approved Ruconest, the first recombinant C1-Esterase Inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). [More]
GSK begins shipment of flu vaccines to U.S. for the upcoming 2014-15 season

GSK begins shipment of flu vaccines to U.S. for the upcoming 2014-15 season

GSK announced today it has begun shipping FLUARIX QUADRIVALENT (Influenza Vaccine) doses to U.S. healthcare providers. This is the first shipment of GSK’s U.S. flu vaccine supply for the flu season, following licensing and lot-release approval from the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research. [More]
Paracetamol safety and osteoarthritis: an interview with Professor David Hunter, University of Sydney

Paracetamol safety and osteoarthritis: an interview with Professor David Hunter, University of Sydney

Firstly, paracetamol has been the first-line recommended treatment for osteoarthritis pain for very many years and, secondly, it is readily available over the counter and can be bought in relatively large quantities. [More]
First step in developing evidence-based concussion guidelines

First step in developing evidence-based concussion guidelines

A research review identifying the clinical indicators most strongly associated with concussion is an important first step in the process of developing evidence-based guidelines for concussion diagnosis, prognosis, and treatment, according to a new report published by Neurosurgery, official journal of the Congress of Neurological Surgeons. [More]

Prisons cut health care costs, but aging inmate population threatens budgets

Health care for prisoners has long taken a bite out of state budgets, but a new report from the Pew Charitable Trusts says prisons have cut back on those costs. They've outsourced some health services, used tele-medicine, and simply incarcerated fewer people. But the aging of the inmate population threatens to drive those costs right back up (Gorenstein, 7/9). [More]